RGNX · REGENXBIO Inc.

Track RGNX — free

$8.56 -0.17 (-1.95%) At close · Sep 10

Russell 2000 member Rebalance outlook locked

Market Cap

$576.30M

66.01M

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$174.48M

Trailing 12 months

Net income (TTM)

−$196.43M

Trailing 12 months

Revenue growth YoY

+405.7%

Year over year

Operating margin

-94.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-43.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$105.52M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.0%

Year over year · more shares

Price change (1Y)

-11.7%

Trailing year

Short interest

11.4%

Latest settlement · 4.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 17.8 · elevated Equity put/call 0.60

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −20%

below

RSI (14) 40

neutral

MACD trend Negative

52-week position 30%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −18%

trailing

6-month return +5%

trailing

YTD return −39%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $11 › 200d $10 — 50d above 200d

Institutional flow Distributing

-8% holders QoQ · +25 funds added

Insider flow Accumulating

Net +$260.6K over 90 days · 50% sells

Short interest Falling

11.36% of float · ▼ -8.5% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

166 holders — mid 3-yr range

Squeeze score 59

elevated · 0–100

Fundamentals

Strong

Revenue growth +126%

Y/Y

EPS growth +18%

Y/Y

Free cash flow $-126.4M

Quant / Vol

risk profile

Very High

Volatility 94%

annualized · 1-yr

Max drawdown −65%

past year

ATR 8.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−20% Bearish

RSI (14)

40 Neutral

MACD trend

Negative Bearish

52-week position

30% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $11 › 200d $10 — 50d above 200d

Institutional flow Distributing

-8% holders QoQ · +25 funds added

Insider flow Accumulating

Net +$260.6K over 90 days · 50% sells

Short interest Falling

11.36% of float · ▼ -8.5% MoM · 4.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

166 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $6 Now $9 · 30% Range high $16

vs 200-day avg -15% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RGNX REGENXBIO Inc. this stock	$576.30M	-39.4%	+126.5%	—	11.4%
VRTX Vertex Pharmaceuticals Inc / Ma	$132.08B	+14.9%	+46.2%	30.4	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$83.15B	+4.6%	+20.8%	20.0	2.5%
ARGX Argenx SE	$62.33B	+17.0%	—	—	2.0%
CSLLY Csl Ltd	$58.10B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

166

% held: 65.0%
Net QoQ: -406.7K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

194

View

Short & Settlement

Short Interest Falling

Shares short

7.5M

Days to cover: 4.9d
Change: -700.3K sh

View

Short Volume

Short vol %

58%

As of: Sep 10, 2026

Short Total

View

Fails to Deliver

FTD shares

26.3K

Value: $287.0K
As of: Aug 13, 2026

View

Off-Exchange

Off-exchange %

35.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$260.6K

Buyers / Sellers: 1 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$170.4M

Net income (FY): $-193.9M
EPS diluted: $-3.76

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 25, 2026
This year: 15

View

Proposed Sales

Value

$517.6K

Shares: 43.2K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
RGNX	-6.3%	-18.0%	+5.4%	-8.1%	-39.4%
SPY	+0.1%	-1.1%	+15.3%	-0.6%	+11.8%
vs SPY	-6.4%	-17.0%	-9.8%	-7.5%	-51.2%

Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 99 filings 99 filers Visit website Investor relations

RGNX · REGENXBIO Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance